Emergent BioSolutions Suspends CDMO Guidance As It Awaits Clarity On COVID-19 Vaccine Requirements

  • Emergent BioSolutions Inc EBS reported Q1 sales of $307.5 million, down 10% Y/Y, beating the consensus of $283 million.
  • Total product sales increased 72% to $237.1 million, while Contract development & manufacturing (CDMO) revenues declined 67% to $60.8 million.
  • The decrease is primarily due to the company's decision to initiate maintenance and other modification-related work at the Bayview facility, which reduced manufacturing activities during the quarter.
  • Adjusted EPS fell 88% to $0.18, beating the consensus of $0.12.
  • The company reported an adjusted EBITDA of $36 million, down from $123.5 million a year ago.
  • The gross margin compressed from 69% to 48%.
  • Guidance: Following the recent decision by Johnson & Johnson JNJ to suspend projecting COVID-19 vaccine sales for 2022 due to global supply surplus and vaccine hesitancy, EBS's FY22 revenues related to its commercial supply arrangement with J&J are uncertain. 
  • Hence the company has temporarily suspended guidance for FY22 pending further clarity on J&J COVID-19 vaccine requirements:
  • Price Action: EBS shares are down 9.34% at $33.19 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareSmall CapMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!